Skip to main content
CITIUS ONCOLOGY, INC. logo

CITIUS ONCOLOGY, INC. — Investor Relations & Filings

Ticker · CTOR ISIN · US17331Y1091 US Manufacturing
Open in API
Filings indexed 232 across all filing types
Latest filing 2026-06-01 Capital/Financing Update
Country US United States of America
Listing US CTOR

About CITIUS ONCOLOGY, INC.

https://citiusonc.com/

Citius Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative targeted oncology therapies. Its lead product, LYMPHIR™ (denileukin diftitox-cxdl), is a targeted immune therapy approved by the U.S. Food and Drug Administration (FDA) in August 2024. LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The company's strategy involves expediting development pathways for treatments with reduced clinical risks and securing competitive advantages through intellectual property and regulatory exclusivity. Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals, Inc.

Recent filings

Filing Released Lang Actions
424B3
Capital/Financing Update Classification · 85% confidence The document is a Form S-1 Prospectus Supplement (Rule 424(b)(3)) and a related Form 8-K disclosing the exercise of warrants, the issuance of shares, net proceeds (~$6.1 million), and amendments to the original prospectus. It is not a standalone financial report but rather a securities offering document updating investors on a capital raising transaction. This aligns with the "Capital/Financing Update" category.
2026-06-01 English
CURRENT REPORT
Regulatory Filings Classification · 94% confidence The document is a Form 8-K current report filed with the SEC, disclosing “Other Events” (a press release regarding a clinical data presentation) and listing exhibits. It does not present full financial statements or an earnings summary, nor is it a proxy, dividend notice, or specific governance disclosure. It is a standard regulatory filing under the Exchange Act and does not fit any more specific category, so it falls into the fallback category Regulatory Filings (RNS).
2026-06-01 English
REGISTRATION STATEMENT
Share Issue/Capital Change Classification · 88% confidence The document is a Form S-3 registration statement and preliminary prospectus filed with the SEC under the Securities Act of 1933. It details the registration of up to 32,931,482 shares of common stock (issuable upon exercise of warrants and conversion of loans) for resale by selling stockholders. This is not a financial report, proxy solicitation, or earnings release but a registration/prospectus for share issuance/resale, fitting the “Share Issue/Capital Change” category (Code: SHA).
2026-05-29 English
PROSPECTUS SUPPLEMENT
Interim / Quarterly Report Classification · 90% confidence The text includes a clear heading “FORM 10-Q” and contains unaudited quarterly financial statements (balance sheet, statements of operations, MD&A, risk factors, legal proceedings, use of proceeds, etc.) for the period ended March 31, 2026. This is exactly the statutory quarterly report required by Section 13 or 15(d) of the Securities Exchange Act. Therefore, it should be classified as an Interim/Quarterly Report. Q2 2026
2026-05-22 English
CURRENT REPORT
Regulatory Filings Classification · 85% confidence The document is a US Securities and Exchange Commission Form 8-K current report. It references the furnishing of a press release (Exhibit 99.1) announcing Q2 2026 results. It does not itself contain substantive financial statements or the full earnings text, but is a regulatory disclosure filing. Under the classification scheme, there is no dedicated code for Form 8-K, so it falls into the fallback category of general regulatory filings (RNS).
2026-05-15 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2026
2026-05-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.